1-4 of 4
Changhong Yin, MD MS
Close
Sort by
Journal Articles

Ibrutinib Significantly Prolonged Survival in a Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: Ibrutinib May be a Potential Adjuvant Agent in the Treatment of BL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Timmy O'Connell, MS, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2015) 126 (23): 5117.
https://doi.org/10.1182/blood.V126.23.5117.5117
Published: 2015
Journal Articles

Ibrutinib Alone and in Combination with Dexamethasone and Carfilzomib Significantly Inhibits Cell Proliferation in Primary Mediastinal B-Cell Lymphoma (PMBL): Ibrutinib May be a Future Targeted Agent in Combination Therapy in Patients with PMBL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Lauren Harrison, RN, MSN, Carmella van de Ven, MA, Matthew J. Barth, MD, Rodney R. Miles, MD PhD, Paul J. Galardy, MD, Stanton Goldman, MD, Megan S Lim, MD PhD, Michelle L. Hermiston, MD PhD, Linda McAllister-Lucas, MDPhD, Lisa Giulino-Roth, MD, Sherrie L. Perkins, MD PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2015) 126 (23): 4852.
https://doi.org/10.1182/blood.V126.23.4852.4852
Published: 2015
Journal Articles

Downregulation of DLEU1 Significantly Shortened Survival in a Rituximab-Treated DLEU1 Knockout Human Burkitt Lymphoma (BL) Xenograft NSG Mouse Model: DLEU1 May Act As a Tumor Suppressor Gene in Pediatric BL

Sanghoon Lee, PhD MSc, Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Carmella van de Ven, MA, Mitchell S. Cairo, MD
Journal: Blood
Blood (2015) 126 (23): 3656.
https://doi.org/10.1182/blood.V126.23.3656.3656
Published: 2015
Journal Articles

Ruxolitinib Significantly Prolongs Survival in Both a Primary Mediastinal B-Cell Lymphoma (PMBL) and Hodgkin Lymphoma (HL) Xenograft NSG Mouse Model: Ruxolitinib May be a Potential Adjuvant Agent in the Treatment of PMBL and of HL

Sanghoon Lee, PhD MSc., Changhong Yin, MD MS, Janet Ayello, MS, Erin Morris, RN, Carmella van de Ven, MA, Mitchell S. Cairo, MD
Journal: Blood
Blood (2015) 126 (23): 2732.
https://doi.org/10.1182/blood.V126.23.2732.2732
Published: 2015